An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DermTech Presents in Expert Panel at Inaugural Alliance for Innovation in Integrated Healthcare Summit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
DermTech (NASDAQ: DMTK) participated in the inaugural Alliance for Innovation in Integrated Healthcare Summit on October 11, 2021. Senior VP Dan Visage was part of a panel discussing the impact of technology in dermatologic treatments.
The summit gathered leaders from various sectors to address challenges in healthcare innovation. DermTech aims to enhance precision dermatology through its non-invasive skin genomics platform.
Positive
DermTech's participation in a significant healthcare summit enhances its visibility in innovation discussions.
Dan Visage's presence on the expert panel showcases the company's leadership in technological advancements in dermatology.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the Company’s participation in the inaugural Alliance for Innovation in Integrated Healthcare’s Summit & Educational Program. The hybrid event featured a series of presentations by key leaders in payer, provider, pharmaceutical, legal, government and other healthcare sectors, who discussed their innovation plans.
Dan Visage, senior vice president of Payer Access at DermTech, served on a panel of experts, titled “Diagnostic Disruption.” Other panel members include Peter Wood, vice president of Pipeline Development at Exact Sciences Corporation, Illumina, Inc. Vice President and Global Head of Market Access, Amma Qadan, and Allison Martin, founder and executive director of Recuro Health, Inc. The panel, which took place on October 11, 2021, discussed ways advances in technology are changing the landscape of dermatologic treatments, and provided insight into key industries that are leading innovation.
“The AIIH Summit brings together leaders and stakeholders in healthcare to engage in provocative, open and transparent discussions,” said Visage. “It was an honor to participate in the panel on behalf of DermTech, and to address core challenges facing healthcare, as we evaluate new and emerging services and technology.”
For more information about DermTech, please visit: www.dermtech.com.
About DermTech:
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.
Forward-Looking Statements:
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost‑effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
What are DermTech's recent activities related to healthcare innovation?
DermTech recently participated in the Alliance for Innovation in Integrated Healthcare Summit on October 11, 2021, discussing technological advancements in dermatologic treatments.
Who represented DermTech at the AIIH Summit?
Dan Visage, Senior VP of Payer Access, represented DermTech at the AIIH Summit.
What was the focus of the panel discussion involving DermTech at the summit?
The panel discussed 'Diagnostic Disruption', focusing on how technology is transforming dermatological treatments.
How does DermTech contribute to precision dermatology?
DermTech uses a non-invasive skin genomics platform to improve skin cancer detection and create targeted treatments.
